Home >> Tag Archives: Agilent Technologies

Tag Archives: Agilent Technologies

Agilent, Incyte collaborate to develop CDx

March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.

Read More »

Newsbytes

April 2023—At the medical center of the University of Medicine and Pharmacy at Ho Chi Minh City, patients are not screened for bladder cancer using urine cytology because the pathology department does not have the capability for such screening. But that may soon change, thanks to an organization focused on using digital pathology to increase the availability of pathology education resources in developing countries.

Read More »

Agilent releases on-deck thermal cycler for Bravo NGS platform

March 2023—Agilent Technologies released an on-deck thermal cycler that integrates with the company’s Bravo NGS automated liquid handling platform. The optional acces­sory enables the Bravo platform to provide thermal cycling as part of an automated protocol and extends walkaway time. The setup is beneficial, the company says, for applications such as library preparation and target enrichment steps in next-generation sequencing workflows, end-point PCR, and cell-based applications.  

Read More »

Agilent, Akoya to develop multiplex IHC solutions

February 2023—Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. The agreement aims to deliver an end-to-end multiplex solution integrating Agilent’s Dako Omnis staining instrument and Akoya’s PhenoImager HT imaging platform.  

Read More »

Agilent releases SureSelect RNA reagent kit

October 2020—Agilent Technologies released the Sure­Select XT HS2 RNA reagent kit. The kit enables users to accurately profile gene expression and detect RNA fusions using low-input FFPE samples and aims to significantly improve efficiency, especially in labs that process both DNA and RNA samples for next-generation–sequencing applications.

Read More »

Newsbytes

R programming language gains steam in pathology labs April 2020—Among laboratories focused on expanding data analytics, the statistical programming language R has a loyal user base that is steadily growing. “There is a crew of us that are really trying to show the utility of R for laboratories,” says Stephen Master, MD, PhD, chief of the Division of Laboratory Medicine and director of the Michael Palmieri Laboratory for Metabolic and Advanced Diagnostics at Children’s Hospital of Philadelphia.

Read More »

Agilent CDx gets expanded approvals

December 2019—The FDA approved Agilent Technologies’ PD-L1 IHC 22C3 pharmDx assay as an aid in identifying patients with esophageal squamous cell carcinoma for treatment with Keytruda (pembrolizumab), an anti-PD-1 therapy manufactured by Merck. Keytruda is approved for patients with recurrent locally advanced or metastatic ESCC whose tumors express PD-L1 (combined positive score ³10), as determined by an FDA-approved test, with disease progression on or after one prior line of systemic therapy.

Read More »

Agilent companion Dx gets expanded approval

August 2018—Agilent Technologies announced that the FDA has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use. PD-L1 IHC 22C3 pharmDx is a laboratory test doctors can use to identify the protein programmed cell death ligand 1 in tumor tissue obtained from patients with lung and gastric cancer.

Read More »

Newsbytes, 7/15

July 2015—Why Sonora Quest gave itself high marks for LIS conversion; Pathologists share homegrown software for infant autopsies; CMS promotes innovation by offering data to private sector; Agilent purchases Cartagenia; Database provides information from next-gen sequencing

Read More »

SureFISH probes, 3/14

March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.

Read More »

Strand-specific RNA library prep kit, 4/13:86

Agilent Technologies’ SureSelect strand-specific RNA library preparation kit for whole transcriptome and targeted RNA sequencing allows researchers to prepare high-quality, strand-specific libraries for next-generation sequencing. The ability to gain strand-specific information from RNA sequencing experiments allows researchers to more easily discern overlapping transcripts and investigate antisense expression to better understand gene regulation.

Read More »

Exome kits, software for next-gen sequencing, 4/13:84

Agilent Technologies’ HaloPlex exome kits and SureCall software complement the company’s Web-based SureDesign interface and custom HaloPlex gene panels to provide a complete, integrated workflow. The HaloPlex exome kit comprises about 2.5 million probes to provide comprehensive coverage of the coding regions of the human genome with minimal hands-on time. The kit requires only 200 ng of input DNA.

Read More »
CAP TODAY
X